Effects of the Change in Cutoff Values for Human Epidermal Growth Factor Receptor 2 Status by Immunohistochemistry and Fluorescence In Situ Hybridization A Study Comparing Conventional Brightfield Microscopy, Image Analysis-Assisted Microscopy, and Interobserver Variation

被引:24
作者
Atkinson, Roscoe [2 ,5 ]
Mollerup, Jens [3 ]
Laenkholm, Anne-Vibeke [4 ]
Verardo, Mark [5 ]
Hawes, Debra [2 ]
Commins, Deborah [2 ]
Engvad, Birte [6 ]
Correa, Adrian [2 ]
Ehlers, Charlotte Cort [7 ]
Nielsen, Kirsten Vang [1 ]
机构
[1] Dako Denmark AS, Dept Res & Dev, Res & Dev, DK-2600 Glostrup, Denmark
[2] Univ So Calif, Dept Pathol, Los Angeles, CA 90089 USA
[3] Dako Denmark AS, Dept Clin Affairs, DK-2600 Glostrup, Denmark
[4] Rigshosp, Dept Pathol, DK-2100 Copenhagen, Denmark
[5] Dako N Amer Inc, Carpinteria, CA USA
[6] Odense Univ Hosp, Dept Pathol, DK-5000 Odense, Denmark
[7] Hillerod Hosp, Dept Pathol, Hillerod, Denmark
关键词
HUMAN-BREAST-CANCER; GUIDELINE RECOMMENDATIONS; ADJUVANT CHEMOTHERAPY; HER2; TRASTUZUMAB; AMPLIFICATION; ASCO/CAP; TISSUE; SURVIVAL; THERAPY;
D O I
10.5858/2010-0462-OAR
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Context.-New guidelines for HER2 testing have been introduced. Objectives.-To evaluate the difference in HER2 assessment after introduction of new cutoff levels for both immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) and to compare interobserver agreement and time to score between image analysis and conventional microscopy. Design.-Samples from 150 patients with breast cancer were scored by 7 pathologists using conventional microscopy, with a cutoff of both 10% and 30% IHC-stained cells, and using automated microscopy with image analysis. The IHC results were compared individually and to HER2 status as determined by FISH, using both the approved cutoff of 2.0 and the recently introduced cutoff of 2.2. Results.-High concordance was found in IHC scoring among the 7 pathologists. The 30% cutoff led to slightly fewer positive IHC observations. Introduction of a FISH equivocal zone affected 4% of the FISH scores. If cutoff for FISH is kept at 2.0, no difference in patient selection is found between the 10% and the 30% IHC cutoff. Among the 150 breast cancer samples, the new 30% IHC and 2.2 FISH cutoff levels resulted in one case without a firm diagnosis because both IHC and FISH were equivocal. Automated microscopy and image analysis-assisted IHC led to significantly better interobserver agreement among the 7 pathologists, with an increase in mean scoring time of only about 30 seconds per slide. Conclusions.-The change in cutoff levels led to a higher concordance between IHC and FISH, but fewer samples were classified as HER2 positive. (Arch Pathol Lab Med. 2011;135:1010-1016)
引用
收藏
页码:1010 / 1016
页数:7
相关论文
共 26 条
[1]   Enhanced accuracy and reliability of HER-2/neu immunohistochemical scoring using digital microscopy [J].
Bloom, K ;
Harrington, D .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2004, 121 (05) :620-630
[2]  
Bose S, 2001, Breast J, V7, P337, DOI 10.1046/j.1524-4741.2001.21018.x
[3]   HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: Impact on selecting patients for herceptin therapy [J].
Brunelli, Matteo ;
Manfrin, Erminia ;
Martignoni, Guido ;
Bersani, Samantha ;
Remo, Andrea ;
Reghellin, Daniela ;
Chilosi, Marco ;
Bonetti, Franco .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2008, 129 (06) :907-911
[4]   Prediction of HER2 gene status in Her2 2+invasive breast cancer: a study of 108 cases comparing ASCO/CAP and FDA recommendations [J].
Chibon, Frederic ;
de Mascarel, Isabelle ;
Sierankowski, Ghislaine ;
Brouste, Veronique ;
Bonnefoi, Herve ;
Debled, Marc ;
Mauriac, Louis ;
MacGrogan, Gaetan .
MODERN PATHOLOGY, 2009, 22 (03) :403-409
[5]   Systematic Review of HER2 Breast Cancer Testing [J].
Cuadros, Marta ;
Villegas, Roman .
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2009, 17 (01) :1-7
[6]   Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis [J].
Dendukuri, Nandini ;
Khetani, Karim ;
McIsaac, Michelle ;
Brophy, James .
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2007, 176 (10) :1429-1434
[7]   Disease-Free Survival According to Degree of HER2 Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial [J].
Dowsett, Mitch ;
Procter, Marion ;
McCaskill-Stevens, Worta ;
de Azambuja, Evandro ;
Dafni, Urania ;
Rueschoff, Josef ;
Jordan, Bruce ;
Dolci, Stella ;
Abramovitz, Mark ;
Stoss, Oliver ;
Viale, Giuseppe ;
Gelber, Richard D. ;
Piccart-Gebhart, Martine ;
Leyland-Jones, Brian .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18) :2962-2969
[8]  
*EMEA, 2005, HERC PROD INF
[9]   HER2+breast cancer [J].
Hicks, David G. ;
Kulkarni, Swati .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2008, 129 (02) :263-273
[10]   New cutpoints to identify increased HER2 copy number: analysis of a large, population-based cohort with long-term follow-up [J].
Jensen, K. C. ;
Turbin, D. A. ;
Leung, S. ;
Miller, M. A. ;
Johnson, K. ;
Norris, B. ;
Hastie, T. ;
McKinney, S. ;
Nielsen, T. O. ;
Huntsman, D. G. ;
Gilks, C. B. ;
West, R. B. .
BREAST CANCER RESEARCH AND TREATMENT, 2008, 112 (03) :453-459